Biotech Values

[DewDiligence]

GLYC/PFE—Rivipansel fails phase-3 in SCD:

https://www.businesswire.com/news/home/20190802005512/en

GlycoMimetics…reported that Pfizer Inc. announced today that the Phase 3 Rivipansel…pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with intravenous (IV) opioids. The primary endpoint was time to readiness-for-discharge and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids.